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Introduction
Th e possibility of tissue repair by autologous adult pro-
genitor cells immediately captured the attention of 
clinicians confronted with the disabling, life-threatening 
circumstance of heart failure. During the last ﬁ ve years, 
more than a dozen clinical studies using bone marrow 
cells have been published, ranging from case reports to 
formal trials, deploying a range of diﬀ ering cell-based 
therapies with the shared objective of improving cardiac 
repair [1].
Although most of these initial human trials suggest 
functional improvement, randomized clinical trials 
reported contradictory results [2, 3] suggesting that the 
ideal protocol design still needs to be deﬁ ned, with the 
help of large animal models [4]. Several issues have been 
identiﬁ ed by the European task force in translational 
research in the heart [5], including the type of cells to be 
used, the route of delivery, the number of cells and the 
volume to be given.
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Our aim was, with an experimental design of acute 
myocardial infarction (MI) and autologous cardiac cell 
therapy that closely match clinical trials [2, 3] to analyze 
and quantify whole body and heart distribution of injected 
autologous bone marrow-mononuclear cells (BM-MNCs). 
We also evaluated the optimal route of delivery 
(intracoronary versus peripheral intravenous injection).
Materials and methods
Animal procedures
Animal procedures were approved by the Institutional 
Committee for Use and Care of Laboratory Animals at the 
Veterinary School of Nantes and conform to the Guide for 
the Care and Use of Laboratory Animals (NIH Publication 
No.85-23, revised 1996). Forty-six domestic pigs (35 to 40 
kg) were included in the study. For MI induction and cell 
injection, anesthesia was induced by intramuscular injec-
tion of ketamine (10 mg/kg)/xylazine (2 mg/kg) and main-
tained with mechanical tracheal venti la tion using inhaled 
isoﬂ urane (2%). All animals received subcutaneously 
morphine (0.2 mg/kg) prior and after all procedures.
Experimental myocardial infarction
We used the MI experimental model initially described 
by Suzuki et al [6], with slight modiﬁ cations. Five days 
prior MI induction, animals received β-blocker carazolol 
(20 μg/kg) twice per day. Propranolol (0.05 mg/kg) was 
injected intravenously just before MI induction 
procedure to prevent arrhythmia. After the placement of 
a 6F sheath in the femoral artery, an extra-back up 6F 
guiding catheter (Boston Scientiﬁ c Scimed, Inc, Boston, 
USA) was placed under ﬂ uoroscopy into the left main 
coronary artery. A 3 mm over the wire balloon catheter 
was placed either into the left anterior descending 
coronary artery distal to the ﬁ rst diagonal branch or into 
the left circumﬂ ex. After balloon inﬂ ation a coronary 
thrombus was induced by injections below the balloon of 
thrombin (900 UI, Sigma Aldrich Corporation, Saint 
Quentin Fallavier, France) and ﬁ brinogen (5 mg, Sigma). 
Th e balloon was deﬂ ated two to three minutes after 
injections. Coronary occlusion was checked by angio-
gram, and MI was conﬁ rmed by ECG alteration and by 
plasma creatine kinase elevation 24 hours after MI induc-
tion (Reﬂ otron, Roche Diagnostics, Meylan, France).
Preparation and cryopreservation of autologous bone 
marrow mononuclear cells (BM-MNCs)
Five days after MI, a total of 100 mL of bone marrow was 
aspirated into heparin-treated Bone Marrow Aspiration/
Intraosseous Infusion needle (15Ga, 10mm, Cardinal 
Health France 205 S.A.S, Châteaubriand, France) from 
the iliac crests and shoulder blades under general 
anaesthesia. Five points of puncture were performed at 
each site of 5 mL each. Th e duration of the procedure was 
15 to 20 minutes. BM-MNCs were isolated using Ficoll 
gradient (Eurobio Les Ulis, France), and a total of 244 x 
106 ± 33 x 106 BM-MNCs was obtained.
BM-MNCs were cryopreserved in foetal calf serum 
10% DMSO. Cryo-preservation for two days avoided two 
general anaesthesias the same day in seriously disabled 
animals and decreased the number of red blood cells to 
be injected.
Dual fl uorescence and radioactive labelling
Seven days after MI induction, BM-MNCs were quickly 
thawed and labeled immediately before injection using a 
green intracellular ﬂ uorescent dye, Carboxy Fluorescein 
diacetate Succinimidyl Ester (CFSE, Molecular Probes 
Invitrogen, Cergy Pontoise, France) [7].
99mTechnetium (99mTc) labeling was performed after 
CFSE labeling, using the IsolinkTM kit according to the 
manufacturer’s instructions (Mallinckrodt Medical B.V., 
Petten, the Netherlands). CFSE + BM-MNCs were 
incubated with IsolinkTM/99mTc for 40 minutes at 37°C and 
pH = 6. Before injection, BM-MNCs were centrifugated 
and resuspended in 10 mL NaCl to obtain a ﬁ nal solution 
containing 300-400 MBq 99mTc-CFSE + BM-MNCs. Less 
than 5% cell mortality was observed in all experiments 
using trypan blue exclusion method after thawing, after 
radiotracer and ﬂ uorescence labeling, and immediately 
before injection.
99mTc cell leakage was evaluated before injection and 
after four hours incubation at 37°C in vitro. Every hour, 
supernatant was collected. 99mTc activities were quantiﬁ ed 
on both supernatant and BM-MNC pellet using a gamma 
counter. Radio-labeling eﬃ  cacy, deﬁ ned as the percentage 
of 99mTc cell activity in the ﬁ nal cell solution, was 98 ± 5% 
(n = 3) after four hours and was stable during the four 
hour experiment, suggesting no 99mTc cell leakage.
Autologous BM-MNC injection
At Day 7 after MI, a second catheterization was per-
formed. A 3 mm over the wire balloon catheter was 
advanced to the site of MI induction. An angiogram was 
performed before completing the procedure. In the 
absence of coronary reperfusion, a recanalization was 
performed with the guide wire before its distal place ment. 
BM-MNCs were injected less than 30 minutes after 
preparation. Th e balloon was inﬂ ated at low pressure (two 
bars) and 3.3 mL of labeled BM-MNCs were injected 
through the lumen. Th e balloon was deﬂ ated two to three 
minutes later. Th e same procedure was repeated three 
times with a two minute interval between procedures. A 
total of 108 BM-MNCs were injected in 10 mL of NaCl at a 
ﬁ nal concentration of 107 BM-MNCs/mL.
For intravenous delivery, 108 BM-MNCs were injected 
via the superﬁ cial vein of the left front leg, using a bolus 
injection of 15 seconds.
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Nuclear imaging and gamma counting
Planar scintigraphic images of 99mTc-BM-MNC body 
distri bution were obtained 1hour and 24 hours after 
tracer injection, using a gamma camera ﬁ tted with a low 
energy all purpose high resolution parallel hole collimator 
(DS7, Sopha Medical, GEMS, Buc, les Yvelines, France). 
Th e energy window was centred at 140 keV ± 20%. Using 
a dedicated image processing co mputer, a static image 
was recorded into a 64 × 64 matrix for 35 seconds. Th e 
camera was calibrated using a standard source measured 
with a gamma counter before each acquisition to convert 
image counts to activity in MBq. For each experiment a 
calibrated dose of technetium was used to quantify 
activity decay after 24 hours. Anesthetized animals were 
positioned in supine positions, at a constant distance of 
30 cm from the collimator, and images were recorded in 
thoracic and abdominal projections. On each image, a 
region of interest was drawn around each organ to 
quantify counts within the drawn area. Organ activity in 
each region of interest was expressed as the percentage of 
the total initial injected activity (measured as the 
diﬀ erence between the 99mTc-BM-MNCs syringe content 
before and after injection) with correction for 99mTc 
physical decay.
Animals were sacriﬁ ced, their organs were excised and 
imaged with the gamma camera, and activity was 
measured in weighted samples of each organ and used to 
quantify organ gamma counting radioactivity (ACAD 
activimeter, Lemer Pax, Nantes, France). All quantitative 
analyses were performed by two investigators blinded to 
animal treatment group.
Pathologic examination and immunohistology
Animals were sacriﬁ ced 1 hour or 24 hours after BM-
MNC injection. Heart samples were cryopreserved and 
sliced into contiguous transverse 5 μm thick cryosections 
or were embedded in paraﬃ  n and stained with 
Hematoxylin-Eosin-Safran (HES). Immunolabeling was 
performed to detect VonWillebrand Factor antibody 
(DakoCytomation SA. France, Trappes France). Cell 
nuclei were labeled using propidium iodide. Histology 
analyses were performed by two pathologists blinded to 
animal treatment group.
Statistical analysis
Data were expressed as mean ± SD. Th e Kruskal-Wallis 
test was used for comparison of independent samples and 
Spearman’s test for correlation coeﬃ  cient. A value of 
P <0.05 was considered statistically signiﬁ cant.
Results
Procedural results
Myocardial infarction was induced in 37/46 pigs 
(Figure  1A). MI induction was complicated by death 
related to ventricular ﬁ brillation during the procedure in 
eight cases (21.6%), and immediately after at the wake up 
time in four other cases (10.8%). Total death rate was 32% 
during and immediately after MI induction, probably due 
to extended MI [8].
Th e 25 surviving animals were randomly assigned to 
three diﬀ erent groups: ﬁ ve were used as controls (MI 
without BM-MNC injection), 16 received intracoronary 
BM-MNCs, four received intravenous BM-MNCs. Two 
deaths were observed during balloon inﬂ ation for 
BM-MNC intracoronary injection (one from a ventricular 
ﬁ brillation and one from a second MI, probably related to 
the injection site location being within a non-infarcted 
area). In the 9/47 animals without MI induction, seven 
received intracoronary BM-MNC injection and two were 
used as radioactivity controls (intracoronary injection of 
IsolinkTM/99mTc only).
Myocardial infarction model
MI was induced by complete obstruction of the left 
coronary artery using balloon inﬂ ation and injection of 
thrombin and ﬁ brinogen (n = 23; left anterior descending 
artery: n = 15; left circumﬂ ex artery: n = 8) (Figure 1B). 
Transient ST-segment elevation and isolated ventricular 
extrasystoles occurred during each coronary balloon 
occlusion, but abnormal ECG proﬁ le (ST-segment eleva-
tion) persisted only after injections of thrombin and 
ﬁ brinogen. Plasma creatine kinase levels increased 
24  hours after coronary occlusion (1,222 ±  604 UI/l 
before coronary occlusion, and 4060 ± 1961 UI/l at 
24  hours, P <0.01), conﬁ rming MI induction. Macro-
scopic examination of the heart performed seven to eight 
days after coronary occlusion showed extensive trans-
mural antero-inferior MI encompassing 41.25 ± 5% of left 
anterior ventricle area (n = 23), with a thinning of the 
injured wall. Statistical analysis did not show any 
diﬀ erence in MI size between animal groups, nor 
between animals with left anterior descending artery or 
left circumﬂ ex coronary occlusion, nor between animals 
with or without spontaneous reperfusion at the time of 
cell injection (not shown). Histopathologic examination 
conﬁ rmed MI, with associated inﬂ ammatory reaction 
and loss of cardiomyocyte nuclei (Figure 1C). Coronary 
angiography at seven days after MI showed spontaneous 
reperfusion in 18/23 pigs. Histological analyses showed 
an adherent residual thrombus within the coronary 
artery without total occlusion of the vessel lumen. 
Coronary occlusion in the ﬁ ve out of 23 remaining pigs 
required reperfusion before BM-MNC injection. 
Neither in pigs with spontaneous reperfusion nor in 
those with mechanical reperfusion, angiographic 
control showed abnomalities of blood ﬂ ow distribution 
when compared to basal angiographic data obtained 
before MI induction.
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Biodistribution and 99mTc-BM-MNC cardiac engraftment 
after MI and intracoronary injection
Scintigraphic images were used to track 99mTc-BM-MNCs 
after intracoronary injection. Radioactivity in the kidneys 
and the bladder due to free 99mTc clearance, was observed 
15 minutes after injection (Figure 2A). At one hour after 
injection, whole pig body images revealed intense regional 
accumulation of radioactivity in the heart (Figure 2B). At 
24 hours a persistence of heart and lung radioactivity was 
observed, with a decrease in signal intensity (Figure 2C).
Radioactivity was expressed as the fraction of measured 
radioactivity, decay-corrected and divided by the injected 
radioactivity amount. In the ﬁ rst set of experiments, 
radioactivity was quantiﬁ ed one hour after 99mTc-BM-
MNC intracoronary injection both in regions of interest 
drawn on the planar images and in isolated organs 
Figure 1. Pig model of acute myocardial infarction. A: Experimental design and animal groups. MI = myocardial infarction; IC = intracoronary 
delivery; IV = peripheral intravenous delivery. B: Induction of myocardial infarction. Coronary angiography, before, during, immediately after and 
seven days after occlusion of left anterior descending artery and fi brinogen/thrombin injections. C: HES staining of myocardial tissue seven days 
after MI induction, characterized by a central necrotic zone and an infl ammatory response.
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(Figure 3A). Th ere was no signiﬁ cant diﬀ erence between 
both quantiﬁ cation methods (n = 6, R = 0.94 for heart, 
and R = 0.84 for lungs). Th erefore results from either 
method were used in following experiments. As controls, 
two pigs without MI but with intracoronary injection of 
IsolinkTM/99mTc only were used to quantify free IsolinkTM/99mTc 
ﬁ xation in each organ. At one hour radioactivity rate was 
11.5 ± 2.1% in the heart, 3.5 ± 2.1% in the lungs and 
14.5  ± 2.1% in the liver (Figure 3B), and at 24 hours 
radioactivity rate was null (not shown). Consistent with 
the in vivo scintigraphic images (Figure 2A), after 99mTc-BM-
MNC intracoronary injection high levels of radioactivity 
were measured in the heart (34.8 ± 9.9% of injected 
radioactivity) and in the lungs (32.6 ± 13.9%) (n = 6, 
Figure 3B). Small quantities of radioactivity were ob-
served in other organs (2 ± 1.4% in the liver, 1.7 ± 0.6% in 
the kidneys). Radioactivity was also quantiﬁ ed in the 
infarcted site and in other cardiac tissues (right ventricle, 
healthy left ventricle and auricles, Figure 3C). We 
observed an accumulation of radioactivity in the 
infarcted area, Almost no radioactivity was detected 
remote from injection site (right ventricle, healthy left 
ventricle, auricles). 24 hours after BM-MNC injection, 
radioactivity persisted with lower intensity in the heart 
(6 ± 1.7%) and in the lungs (11 ± 2.6%) (n = 3, Figure 4B).
Importantly, there was no correlation between the 
infarction size and the heart radioactivity rate at one 
hour and 24 hours (not shown).
Myocardial infarction and BM-MNC cardiac engraftment
To investigate the role of MI on BM-MNC homing and 
engraftment in the heart, 99mTc-BM-MNC were intra-
coronary injected in pigs with MI and in pigs without MI. In 
both animal groups, ECG alteration (ST-segment elevation) 
was observed during intracoronary BM-MNC injection. ST-
segment elevation stopped immediately after the procedure, 
suggesting that no micro-infarction was induced by 
injection itself favouring cardiac homing. Importantly, no 
signiﬁ cant diﬀ erence in heart and lung BM-MNC 
distribution was observed between both groups, with a high 
radioactivity ratio in the heart (34.8 ± 9.9% in MI group 
versus 51.2 ± 17.2% in no MI group, Figure 3B).
Biodistribution of BM-MNCs and delivery route
Th e eﬃ  cacy of intracoronary administration versus 
systemic intravenous administration was evaluated in 
pigs with MI. After intravenous cell delivery at 1 hour 
and 24 hours, radioactivity was detected mainly in the 
lungs both on scintigraphic images (n = 4, Figure 4A) and 
by radioactivity quantiﬁ cation, in marked contrast with 
intracoronary injection (Figure 4B). After intravenous 
injection, cardiac radioactivity was almost null (0.16 ± 
0.23%) as compared to pigs after intracoronary injection 
(34.8 ± 9.9%). After 24 hours, no cardiac radioactivity 
was observed in intravenously injected pigs, suggesting 
an absence of cardiac homing at 24 hours.
Histological analyses
For histological analyses, BM-MNCs were labeled with a 
ﬂ uorescent marker (CFSE) prior to injection and animals 
were sacriﬁ ced one hour or 24 hours after injection. As 
noticed by others [9] microscopic ﬂ uorescent artefacts 
were observed in the myocardium of control animals 
with MI and without BM-MNC injection, characterized 
by ﬂ uorescent leukocytes and autoﬂ uorescence within 
the infarcted tissue. However, these artefacts could be 
distinguished from BM-MNCs by their small size and 
their limited location within necrotic areas [10] 
(Figure  5A). BM-MNCs in non necrotic areas were 
detected in each animal that received CFSE+ BM-MNCs 
(Figure 5B-5C), and were not observed in any control 
animals (with MI and without BM-MNC injection, 
Figure  5D). CFSE+ BM-MNCs were also observed in 
heart tissue 24 hours after intracoronary injection in each 
animal that received CFSE+ BM-MNCs (Figure 5J). Th e 
presence of BM-MNCs was conﬁ rmed in HES histo-
logical analyses (Figure 5E-5F). BM-MNCs appeared as 
clusters of mononuclear cells, characterized by round 
Figure 2. 99mTc-BM-MNC biodistribution in animals with myocardial infarction after intracoronary injection. A-B: abdomen (A) and thorax 
(B: anterior and lateral) scintigraphic images at 15 minutes and 1 hour. C: thorax scintigraphic image at 24 hours in the same animal.
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and dense blue nuclei, in contrast with elongated and 
blue pale cardiomyocyte nuclei. Th ese round and dense 
blue nuclei were not observed in control animals in HES 
histologic analyses (not shown). BM-MNCs were located 
in majority in the peri-infarcted myocardium and only a 
few BM-MNCs were detected in infarcted myocardium. 
Figure 3. 99mTc-BM-MNC biodistribution after intracoronary injection in animals with or without myocardial infarction. The percentage of 
radioactivity in organs was calculated by dividing organ radioactivity with the total injected quantity after radioactive decay correction, one hour 
after injection. A: Comparison between two radioactivity quantifi cation methods in the same animal: values from measured radioactivity in isolated 
organs (x-axis), and values from regions of interest drawn in the scintigraphic whole body acquisition images (y-axis). B: Radioactivity quantifi cation 
in animals with (MI) or without (no MI) myocardial infarction, after intracoronary injection of IsolinkTM/99mTc only or 99mTc-BM-MNCs. Bars indicate 
mean and SD (P >0.05, not signifi cant). C: Individual quantities of radioactivity in pigs with or without MI (P >0.05, not signifi cant). Radioactivity was 
quantifi ed in 1 g myocardium inside the infarcted area, in the left and right ventricles distant from infarcted area, and in the left and right auricles.
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No BM-MNCs were observed remote from the injection 
site (auricle, right ventricle, non infarcted myocardium).
Tissue sections were stained for endothelial cells and 
capillaries using anti-VonWillebrand antibody (Figure 5G). 
Neither thrombus nor arterial occlusion was observed in 
both groups. BM-MNCs were incorporated within 
myocardial tissue and were not observed within the 
lumen neither into wall blood vessel, and no cells were 
observed with double staining CFSE+ and endothelial 
marker. Double labeling for macrophages using anti-
MAC-1 antibody was negative (not shown), suggesting 
that transplanted BM-MNCs had not been phagocyted.
We also investigated extracardiac BM-MNC biodistri-
bution by histological analysis. CFSE+ BM-MNCs were 
disseminated in whole lungs (Figure 5H). Sections of 
other vital organs (liver, spleen, kidneys and thymus) 
demonstrated no signiﬁ cant cell location, only cell debris 
(Figure 5I). Importantly, the presence of BM-MNCs was 
conﬁ rmed one hour (Figure 5K-5L) and 24 hours (not 
shown) after intracoronary injection in every pig without 
MI and again, neither thrombus nor arterial occlusion 
was observed. Th ese data were in accordance with 
analyses of scintigraphic data and radioactive organ 
quantiﬁ cation (Figure 3B).
Th e absence of cardiac homing after BM-MNC intra-
venous injection at 24 hours as observed on scintigraphic 
images was also conﬁ rmed by histological analyses, 
showing an absence of ﬂ uorescence in myocardium 
inside and outside MI area (not shown). In contrast, 
CFSE+ BM-MNCs were numerous and dispersed in 
whole lungs when injected intravenously (not shown).
Discussion
In a porcine model of acute MI with late reperfusion and 
autologous cardiac cell therapy, we quantiﬁ ed biodistri-
bution using a radiolabeling technique. Most of the BM-
MNCs delivered by the intracoronary route were 
distributed within the heart and lungs. Th e presence of 
MI did not modify BM-MNC cardiac homing and 
engraftment after intracoronary injection. Finally, 
Figure 4. 99mTc-BM-MNC biodistribution according to delivery route. A: Scintigraphic acquisition images, 1 hour and 24 hours after peripheral 
intravenous 99mTc-BM-MNC injection in the same pig with myocardial infarction. B: Radioactivity quantifi cation, calculated by dividing organ 
radioactivity with the total injected quantity after radioactive decay correction. Bars indicate mean and SD.
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systemic intravenous BM-MNC injection promoted lung 
homing rather than cardiac engraftment.
Th e ﬁ rst prerequisite for cell therapy success is the 
engraftment and thus, homing of transplanted cells to the 
Figure 5. Immunohistologic analyses. Representative organ sections, after intracoronary injection of BM-MNCs labeled prior to injection with 
CFSE (green fl uorescence). Cell nuclei were labeled with propidium iodide (red fl uorescence). A: Fluorescent artefacts within the necrotic area of 
infarcted tissue. B-C: Myocardium sections of infarcted tissue, in absence of necrotic area, one hour after CSFE+ BM-MNC intracoronary injection. 
D: Myocardium section of a control animal (with myocardial infarction, without BM-MNC injection). E-F: The following section of C was stained 
with HES. Engrafted BM-MNCs within the infarcted zone appeared as round and dense blue points (arrow), in contrast to the elongated and 
blue pale cardiomyocyte nuclei (star). G: Myocardium section stained for endothelial cells and capillaries using anti-VonWillebrand antibody (red 
fl uorescence). H-I: Lung (H) and liver (I) section. Cell nuclei labeled with propidium iodide (red fl uorescence). J: Myocardium section of infarcted 
tissue, 24 hours after CFSE+ BM-MNC intracoronary injection. K-L: Myocardium section of an animal without myocardial infarction, one hour after 
CFSE+ BM-MNC intracoronary injection, using VonWillebrand antibody (K) or HES coloration (L).
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target area. Intracoronary delivery oﬀ ers the advantages 
of a non-surgical method that can be performed percu-
taneously during angioplasty for acute MI. In the present 
study we showed that intracoronary BM-MNC injection 
can allow cell engraftment into myocardium tissue, 
whereas peripheral systemic intravenous adminis tration 
was not eﬃ  cient at 24 hours. Th is suggests that the 
cardiac niche eﬀ ect favoured by MI was not suﬃ  cient to 
attract intravenously injected BM-MNCs within 24 
hours, thus limiting the eﬃ  cacy of systemic intravenous 
injection. Chemoattractant factors secreted by the 
infarcted heart might be too diluted in the body of large 
animals like pigs to attract BM-MNCs. If this is the case, 
similar results may be expected in humans. Another 
hypothesis is that the ability to trap intravenously 
injected BM-MNCs within the heart is limited, since only 
4% to 5% of cardiac output is dedicated to supplying the 
coronary arteries [11]). Finally, cardiac engraftment 
following systemic intravenous BM-MNC delivery might 
be limited by lung entrapment prior to coronary artery 
access. Numerous studies have been performed in rodent 
[12] and large animal models [13, 14], using intravenous 
injection of mesenchymal stem cells, showing mesen-
chymal stem cell engraftment after 24 hours. Several 
hypotheses can be discussed to explain these discrepan-
cies with our results. First, our protocol closely matched 
clinical trial protocols, in which a seven-day delay 
between acute MI and cell injection seems to be the best 
time for eﬃ  cacy following intracoronary injection [3, 15]. 
However, this time may be too long after intravenous cell 
injection, in regards to local inﬂ ammatory response and 
niche eﬀ ect. In most studies mesenchymal stem cells 
were injected 1 to 72 hours after myocardial infarction 
[12-14]. Second, BM-MNCs were labeled with 
99mTechnetium, a radioelement that has a short half life 
and may not have been detected at 24 hours. However, 
we did not observe any ﬂ uorescent cell within the heart 
24 hours after intravenous injection, corroborating our 
radioactivity data. Finally, mesenchymal stem cells may 
have a better capability for cardiac homing than BM-
MNCs, that contain a very small stem cell number. 
Interestingly, a recent study comparing intra-aortic, 
intravenous, and intramyocardial delivery of mesen chy-
mal stem cells in rats observed 5% cell survival at 48 hours 
after intravenous delivery, mostly in the lungs [15].
Th e radioactive labeling using IsolinkTM kit did not 
discriminate cell type, and was not species nor cell 
speciﬁ c. In a pilot study we evaluated 99mTc-hexa-methyl-
propylen-amine-oxime (HMPAO) labeling, often used in 
humans. However, 99mTc-HMPAO labeling of BM-MNCs 
was totally unsuccessful (not shown). We then switched 
to the radioactive linker IsolinkTM, which allowed us to 
inject a large quantity of 99mTc-labeled cells, signiﬁ cantly 
higher than in other studies [16, 17]. Although, similar to 
previous studies [11, 18, 19], the viability of IsolinkTM/99mTc-
labeled BM-MNCs was not altered, the adverse eﬀ ects of 
labeling on the migratory and functional abilities of BM-
MNCs cannot be entirely excluded. Th e majority of 
cardiac BM-MNC homing studies were performed in 
rodents, and only a few studies established the fraction of 
transplanted cells retained within the myocardium using 
direct radioactive labeling of the cells. In our study, 
radioactivity quantiﬁ cation in each organ showed 34.8 ± 
9.9% total radioactivity in the heart with an accumulation 
within the injection site, one hour after intracoronary 
BM-MNC injection, and 6.0 ± 1.7% at 24 hours. 
Importantly, histology results were in accordance with 
scintigraphic imaging data conﬁ rming the presence of 
numerous BM-MNCs at one hour and 24 hours after 
intracoronary injection. As in our study, Hou et al [8], 
using a pig model of reperfused MI with intracoronary 
cell delivery and radioactive cell quantiﬁ cation, observed 
a largely right-sided distribution of BM-MNC. However, 
only 2.6 ± 0.3% of BM-MNCs were detected in the heart, 
with some BM-MNCs being distributed to the right 
ventricle. Importantly, the experimental model in this 
study was xenogeneic, with human BM-MNCs being 
injected into pigs. Human cells may lack the correct 
membrane receptors to home into the pig myocardium 
or may undergo acute lysis due to a xenogeneic reaction. 
In a recent study, using a similar model of reperfused MI 
in pigs with autologous BM-MNC transplantation [20] 
6.5% of autologous transplanted BM-MNCs were detected 
in the heart four days after injection, a result close to 
ours at 24 hours. Finally, cardiac homing cell rate at one 
hour might be overestimated by including a possible 
leakage of radioactive label from the cells, although this 
appears unlikely as no radioactive cell leakage was 
observed in vitro in the next four hours following 
radioactive labeling.
Although phase I-II clinical trials have been completed 
using coronary delivery of BM cells, only one study used 
coronary delivery of 99mTc-labeled BM-MNCs (in a single 
patient), and observed intense cardiac cell engraftment 
[17]. Th e study of Hofmann et al [11] showed that in ﬁ ve 
patients with MI, only 1.3 to 2.6% of 18F-FDG-labeled 
BM-MNCs were detected in the infarcted myocardium 
one hour after intracoronary BM-MNC injection. 
However, the number of injected BM-MNCs was 30-fold 
higher than in our study, so the absolute number of 
retained BM-MNCs within the heart was 39 to 78 x 106 
BM-MNCs, a number close to ours (34.8 ± 9.9 x 106 
retained BM-MNCs). Intracoronary injection of a very 
high cell number may saturate the binding sites for 
cardiac cell homing, raising questions about the ideal 
number of cells to be injected.
After intracoronary injection, we observed a similar 
biodistribution of BM-MNCs in animals with or without 
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MI, despite the large size of the infarcted area (45% of the 
left ventricle). Several studies have shown that acute 
myocardial infarction is followed by an acute local 
inﬂ ammatory reaction involving upregulation of chemo-
kines receptors and adhesion molecules, thereby facilitat-
ing adhesion and inﬁ ltration of cells involved in tissue 
repair, including stem cells [21-23]. Th e dynamic capa-
bility of BM-MNCs to migrate and the niche eﬀ ect are 
central in regenerative medicine [21-23]. In our model, to 
carry out intracoronary injection, blood ﬂ ow was stopped 
three times for at least two minutes to prevent backﬂ ow 
and prolong contact time between BM-MNCs and 
myocardium. When BM-MNCs were injected without 
prior MI induction, each maneuver for intracoronary cell 
injection resulted in ST-segment elevation, as already 
described for repeated angioplasty balloon inﬂ ations [24, 
25]. Although we did not evaluate the intensity of the 
ischemia induced by balloon inﬂ ation, this suggests that 
the injection technique created local downstream 
ischemic and preconditioning eﬀ ects [25], thus rendering 
the local microenvironment more receptive to cell 
homing [24]. A recent study in a pig model of myocardial 
infarction and intracoronary injection of autologous BM 
cells, balloon occlusion was found ineﬀ ective to increase 
cell homing [24]. In another study in a similar model, 
single-bolus delivery was as eﬀ ective as three balloon-
occlusion deliveries [26]. Importantly, both studies were 
performed only in pigs with myocardial infarction and 
not in healthy pigs, suggesting that the cardiac niche 
eﬀ ect favoured by MI was suﬃ  cient to attract injected 
BM-MNCs without any further eﬀ ect of balloon 
occlusion. Th e fact that the presence and the size of MI 
did not inﬂ uence cell engraftment could be useful for 
cardiac cell therapy in patients with chronic heart failure 
of non-ischemic origin or with ischemic myocardium 
without myocardial infarction. Two clinical trials have 
been published with patients who have had a myocardial 
infarction at least three months before BM-MNC 
coronary injection [1, 27, 28]. A clinical beneﬁ t was 
observed in both studies, suggesting that BM-MNCs 
homed to the myocardium despite the absence of acute 
myocardial infarction. Th e hypothesis of cardiac homing 
in the absence of acute myocardial infarction was 
recently conﬁ rmed in two Phase I cardiac cell therapy 
clinical trials on patients with chronic ischemic 
cardiomyopathy and receiving an intracoronary injection 
of radiolabeled CD133+ or CD34+ cells [16, 29].
Conclusions
Myocardial cell distribution following intracoronary 
injection did not depend on MI presence. Given these 
results, further eﬀ orts to analyze the mechanisms of 
adhesion and transmigration through the vascular wall 
will be rewarding.
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